Denosumab / Prolia (Bone Biologic)
Common brand names: Prolia (osteoporosis), Xgeva (oncology)
Three nutrients listed against this medication. The most severe is marked critical.
At a glance
One of the three is marked well documented. The other two carry their own evidence levels.
At a glance
- CalciumCritical · Well documented
- Vitamin D3Critical · Traditionally cited, limited evidence
- MagnesiumModerate · Traditionally cited, limited evidence
Color shows how serious each listed effect is. The label beside it shows how strong the evidence is. The cards below explain each one and show its evidence.
Nutrients it can lower
Mechanism, Denosumab powerfully suppresses osteoclast activity, eliminating calcium release from bone resorption. Blood calcium drops significantly. Hypocalcemia is a Black Box Warning.
Common signs, Tetany, muscle cramps, perioral numbness, seizures (severe), cardiac arrhythmia. Potentially fatal hypocalcemia
Fizazi et al. (Lancet, 2011; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 21353695): phase 3 trial of denosumab versus zoledronic acid in prostate cancer bone metastases, in which hypocalcemia was more frequent on denosumab. Hypocalcemia carries a boxed warning in the FDA label, and calcium and 25(OH)D are checked before each injection.
Clinical guidelines call for calcium 1,000–1,200 mg daily with denosumab, started before the first injection.
Mechanism, D3 is required for calcium absorption. Without it, supplemental calcium cannot correct denosumab-induced hypocalcemia. Pre-treatment D3 correction is standard of care.
Common signs, Severe hypocalcemia risk, jaw osteonecrosis, atypical femoral fractures with long-term use
Block et al. (J Bone Miner Res, 2012; PMID 22461041): hypocalcemia occurred in 15% of subjects given a single denosumab dose, and no subject who received adequate calcium and vitamin D supplementation became hypocalcemic. Vitamin D must be replete before dosing: a prerequisite, not a depletion caused by the drug.
25(OH)D is tested first and corrected before the first injection, because Block reports that no subject who received adequate calcium and vitamin D became hypocalcemic. The 30 ng/mL threshold and the D3 2,000–4,000 IU maintenance figure are in common use and are not from a trial cited on this row.
Mechanism, Magnesium is required for PTH secretion and activity. PTH is the primary calcium-regulating hormone. Magnesium deficiency impairs PTH-mediated calcium correction, worsening denosumab-induced hypocalcemia.
Common signs, Worsening hypocalcemia risk, impaired calcium homeostasis
Magnesium supports the PTH response that corrects hypocalcemia; low magnesium worsens denosumab hypocalcemia (mechanistic context). It is not depleted by the drug.
Magnesium 300–400 mg daily is a range in common use, not from a trial cited on this row. The row's own evidence states denosumab does not deplete magnesium.
For your next appointment
It prints or saves as a single page. Whether to add a supplement for a nutrient this medication may lower is a decision for your prescriber.
Disclosure
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →